Latest News
ACQUISITION OF INFANT NUTRITIONAL (“IN”) BUSINESSES FROM NESTLÉ
Australian News, Media Release
The Australian competition authorities have approved Aspen's acquisition of the Australian IN business and the transaction will be effective in Australia from 28 April 2013.
Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg) and Doloxene (dextropropoxyphene napsylate) to remain on ARTG
Australian News, Media Release
On 5th April, 2013 the Administrative Appeals Tribunal (AAT) decided that both Di-Gesic (dextropropoxyphene HCl 32.5 mg/paracetamol 325 mg) and Doloxene (dextropropoxyphene napsylate) should remain on the Australian Register of Therapeutic Goods (ARTG), subject to the implementation of conditions to promote the safe use of these medicines.
Di-Gesic (dextropropoxyphene 32.5mg and paracetamol 325mg) and Doloxene (dextropropoxyphene napsylate100mg) - update 15 March 2013
Australian News, Media Release
Di-Gesic and Doloxene continue to be registered on the Australian Register of Therapeutic Goods (ARTG) and doctors may continue to prescribe both products after carefully considering the indications, warnings and contraindications in the Product Information and Consumer Medicines Information for these products.
BUSPAR (buspirone hydrochloride) supply
Australian News, Media Release
BUSPAR (buspirone hydrochloride) supply + future availability of buspirone through Special Access Scheme (SAS) Aspen is currently unable to manufacture Buspar due to ongoing technical challenges and, more recently, difficulties in sourcing the active ingredient.
Aspen To Continue Appeal Of TGA's Decision
Australian News, Media Release
Aspen will continue to appeal the Therapeutic Goods Administration‟s decision to de-register Di-Gesic and Doloxene.
The TGA has affirmed its decision to cancel the registration of DPP products, however its decision will not take effect until further order of the AAT. Aspen remains concerned to ensure that patients are not left without adequate pain relief, and considers that this is likely to be the case if Di-Gesic and Doloxene are de-registered. Consequently, Aspen will continue its appeal.
Di-Gesic and Doloxene will remain on the register while Aspen‟s appeal is heard and doctors may continue to prescribe both products after carefully considering the indications, warnings and contraindications in the Product Information and Consumer Medicines Information for these products.
Aspen Acquire Portfolio Of 25 GSK Products
Australian News, Media Release
Aspen has reached agreement with GSK to acquire a portfolio of 25 products from GSK for the Australian market, subject to ACCC and Foreign Investment Review Board approval.
Di-Gesic to remain on the market
Australian News, Media Release
Recognising the needs of a small group of patients who would be left without adequate pain relief if DiGesic and Doloxene were no longer available, the Administrative Appeals Tribunal (AAT) has declined to uphold a decision of the Minister/TGA to cancel the registrations of DiGesic and Doloxene.
Aspen Announces Multi-Territory Acquisition Of GSK OTC Products
Australian News, New Zealand News, Media Release
Aspen has acquired a range of OTC products from GSK in a multi-territory transaction.
For Australia, the basket of products has sales of around $17 million, with about $750K in New Zealand. Other Asia-Pacific countries coming under the Aspen Australia umbrella represent sales of around $13.5 million.
The products in Australia are Cartia, Zantac, Lipeze, Quellada and Beconase, all well known power brands which will cement the position of Aspen Australia as one of the leading OTC companies in the country.
Aspen Launch Philippines Business
Australian News, New Zealand News, Media Release
Aspen, Africa’s largest pharmaceutical manufacturer and the biggest listed pharmaceutical group in the health care sector of the Johannesburg Stock Exchange, through Aspen Pharmacare Australia, one of the leading pharmaceutical companies in Australia, aims to make high-quality branded medicine available to Filipino patients at affordable cost through the launch of its local subsidiary, Aspen Philippines.
Australian Packaging Covenant - Aspen Report
Australian News, Media Release
The Australian Packaging Covenant is a voluntary initiative by Government and Industry to reduce the environmental effects of packaging. It is designed to minimise the environmental impacts arising from the disposal of used packaging, conserve resources through better design and production processes and facilitate the re-use and recycling of used packaging materials.
Here you can view Aspen Australia's plan and report.
UPDATE: Important Information regarding Di-gesic and Doloxene.
Australian News, Media Release
UPDATE: We wish to advise you that the Administrative Appeals Tribunal (AAT) has granted Aspen Australia’s application to stay the cancellation of products containing dextropropoxyphene (Di-Gesic and Doloxene) from the ARTG. This allows us the opportunity to have our appeal of the Therapeutic Goods Administration’s (TGA) decision to cancel the registrations heard by the AAT.
South China Morning Post Article
Australian News, New Zealand News, Media Release
In a span of 11 years, Aspen Pharmacare Australia has become one of Australia's leading pharmaceutical companies, developing a reputation for reliable, regulated and affordable medicines. Aspen-marketed brands account for one out of seven prescriptions written in the country.
Business Review Australia Article
Australian News, New Zealand News, Media Release
Aspen Pharmacare Australia Expanding Global Business - from recent acquisition to expansion plans in Asia, Aspen Pharmacare Australia is ready to increase sales and markets.
Aspen Pharmacare Australia announces a new partnership with Eli Lilly Australia for Zyprexa®
Australian News, Announcements
Aspen Pharmacare Australia Pty Ltd (Aspen) is pleased to announce a new partnership with Eli Lilly Australia (Lilly) for Zyprexa® (olanzapine), a market leading medication for schizophrenia and bipolar disorder
Aspen Acquires Sigma's Pharmaceutical Business For AU$900 Million
Australian News, New Zealand News, Media Release
Aspen, South Africa's leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited.
Formal Agreement Reached for $900 Million Sale of Pharmaceuticals Division to Aspen Pharmacare
Australian News, Announcements
On 16 August 2010, Sigma announced that it had agreed in principle to sell its Pharmaceuticals Division to the Aspen Pharmacare Holdings Limited group of companies for A$900 million.
Aspen to distribute Merck products
Australian News, Announcements
Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.
Stephen Saad, CEO of Aspen Holdings, comments on Sigma purchase
Australian News, New Zealand News, Announcements
An interview of Stephen Saad, CEO of Aspen Holdings.
Aspen Announcement to JSE
Australian News, Announcements
Announcement regarding the acquisition of the pharmaceutical business of Sigma Pharmaceuticals Limited by Aspen.
Aspen make a bid for Sigma
Australian News, Media Release
Aspen shareholders are advised that Aspen has submitted an indicative non-binding proposal to acquire, either directly or through a wholly-owned subsidiary, Sigma Pharmaceuticals Limited.
Aspen and GSK Agree On Series Of Strategic Transactions
Australian News, Announcements
Aspen, Africa's largest pharmaceutical manufacturer, has announced that it has agreed to multiple, strategic, inter-dependent transactions with a leading multinational pharmaceutical group, GlaxoSmithKline.
Diversity and Flexibility eNews
Australian News, New Zealand News, Media Release
Aspen's high level of flexibility has shown demonstrable business outcomes in addition to the attraction/retention of diverse talent, including consistently meeting sales objectives and extremely high value customer relationships.
Aspen take on Tritace and Cardizem
Australian News, Media Release
Aspen Pharmacare have signed a licensing agreement with Sanofi-Aventis for the distribution, sales and marketing of Tritace and Cardizem.
Aspen form alliance with Actavis
Aspen Australia have signed a license agreement with Actavis, taking on the sales, marketing and distribution of two products, Neotigason and Rapilysin.
